You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Study design

From: Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

Study Group Vaccine HA dose Schedule
Study in adults D-Pan A/California/7/2009 (H1N1)v-like + AS03A 3.75 μg 2 doses
18-60 year olds Q-Pan A/California/7/2009 (H1N1)v-like + AS03A 3.75 μg 2 doses
Study in children D-Pan0.9 A/California/7/2009 (H1N1)v-like + AS03B 0.9 μg 1 dose
3-9 year olds Q-Pan0.9 A/California/7/2009 (H1N1)v-like + AS03B 0.9 μg 1 dose
  Q-Pan1.9 A/California/7/2009 (H1N1)v-like + AS03B 1.9 μg 1 dose
  1. HA haemagglutinin antigen, AS03 an oil-in-water emulsion containing DL-α-tocopherol and squalene in an aqueous phase with the non-ionic detergent polysorbate80. AS03A contains 11.86 mg DL-α-tocopherolper dose; AS03B contains 5.93 mg DL-α-tocopherol per dose.